The Pharma industry is facing competitive commercial strife, with consumers becoming more and more aware and ruthless. Patients want better treatments, therapies and medicines, at more affordable prices. Customers now want more offers, better medicines and lower-priced drugs.

The vicious and competitive circle of marketing and management is another great worry for the industry. Such a culture which focuses on profit maximisation does not complement research and scientific discovery. 

Even though pharmaceutical companies’ managers constantly seek to improve processes for maximum efficiency, technical contingencies might unfortunately cause a delay in the entire sector.

Pharmaceutical industries are exposed to complex risks concerning drug approval, quality control, supply chain or even the different global commercial practices. 

Due to the pandemic the supply of raw materials were continuously decreasing due to which price of these were rising up, which led to hype in the price of general medicines.